U.S. SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 10-QSB
(MARK ONE)
[X] QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE
ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED NOVEMBER 30, 1999
[_] TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE
ACT OF 1934 FOR THE TRANSITION PERIOD FROM ____________ TO ___________
COMMISSION FILE NUMBER:
L.O.M. MEDICAL INTERNATIONAL, INC.
(Exact name of small business issuer as specified in its charter)
<TABLE>
<CAPTION>
<S> <C> <C>
DELAWARE 98-0178784
(State or other jurisdiction of (Primary Standard Industrial (I.R.S. Employer Identification No.)
incorporation or organization) Classification Code Number)
</TABLE>
580-885 Dunsmuir Street, Vancouver, British Columbia, Canada V6C 1N8
(Address of principal executive offices) (Zip Code)
(604) 602-9400
(Issuer's Telephone Number, including Area Code)
Thomas E. Stepp, Jr.
Stepp & Beauchamp LLP
1301 Dove Street, Suite 460
Newport Beach, California 92660
Telephone: 949.660.9700
Facsimile: 949.660.9010
(Name, Address and Telephone Number of Agent for Service)
APPLICABLE ONLY TO ISSUERS INVOLVED IN BANKRUPTCY
PROCEEDINGS DURING THE PRECEDING FIVE YEARS
Check whether the issuer (1) has filed all reports required to be filed by
Section 13 or 15(d) of the Exchange Act during the past 12 months (or for such
shorter period that the registrant was required to file such reports), and (2)
has been subject to such filing requirements for the past 90 days. [X] Yes [ ]
No
APPLICABLE ONLY TO CORPORATE ISSUERS
State the number of shares outstanding of each of the issuer's classes of common
equity, as of the latest practical date. As of November 30, 1999, there were
5,589,281 shares of the issuer's $.001 par value common stock issued and
outstanding.
<PAGE>
PART I - FINANCIAL INFORMATION
Item 1. Financial Statements
L.O.M. MEDICAL INTERNATIONAL INC.
(A Development Stage Enterprise)
Consolidated Balance Sheet
$ United States
For the six months ended November 30, 1999 and 1998
<TABLE>
<CAPTION>
- -------------------------------------------------------------------------------------------------------
1999 1998
- -------------------------------------------------------------------------------------------------------
Assets
<S> <C> <C>
Current assets
Cash $ 329,516 $ 440,903
Accounts receivable 23,968 16,274
Inventory 100 --
Prepaid expenses 3,352 12,428
- -------------------------------------------------------------------------------------------------------
356,936 469,605
Patent costs (note 3) 14,588 400,445
Capital assets (note 4) 43,730 40,220
- -------------------------------------------------------------------------------------------------------
$ 415,254 $ 910,270
=======================================================================================================
Liabilities and Stockholders' Equity
Current liabilities
Accounts payable and accrued liabilities $ 20,016 $ 13,770
Redeemable preferred shares (note 5) 301,727 309,677
Minority interest (5,536) (5,536)
Stockholders' equity
Capital stock (note 6) 5,619 5,508
Additional paid in capital 1,419,961 1,154,635
Deficit accumulated during the development stage (1,349,859) (574,072)
Accumulated other comprehensive income 23,326 6,288
- -------------------------------------------------------------------------------------------------------
99,047 592,359
- -------------------------------------------------------------------------------------------------------
$ 415,254 $ 910,270
=======================================================================================================
</TABLE>
See accompanying notes to financial statements
On behalf of the Board:
_____________________ Director
_____________________ Director
<PAGE>
L.O.M. MEDICAL INTERNATIONAL INC.
(A Development Stage Enterprise)
Consolidated Statement of Loss
$ United States
For the six months ended November 30, 1999 and 1998
<TABLE>
<CAPTION>
- ------------------------------------------------------------------------------------------------------------------------------------
From Inception
(March 17, 1997) 1999 1998
to November 30, 1999
- ------------------------------------------------------------------------------------------------------------------------------------
<S> <C> <C> <C>
Expenses
Advertising $ 8,230 $ 5 $ 2,365
Amortization 29,778 8,247 8,831
Automotive 34,698 8,187 7,933
Consulting fees 41,870 20,981 10,445
Design plans 10,911 -- --
Director's fees 17,141 1,717 3,452
Foreign exchange (gain) loss (4,184) (1,721) 3,094
Insurance 1,981 -- 188
Interest and bank charges 4,260 2,289 517
Legal and accounting 110,310 28,331 21,288
Licences, fees and dues 1,050 185 288
Management fees 259,761 45,248 35,327
Office and administration 111,785 20,568 31,875
Product development 1,582 -- --
Promotion and entertainment 11,634 1,482 2,133
Rent 82,006 17,717 16,876
Repairs and maintenance 2,150 -- 89
Salaries 31,590 31,590 --
Telephone and utilities 29,523 6,312 6,853
Travel 25,203 10,250 2,396
Video production 20,417 2,929 4,958
- ------------------------------------------------------------------------------------------------------------------------------------
831,696 204,317 158,903
- ------------------------------------------------------------------------------------------------------------------------------------
Loss from operations (831,696) (204,317) (158,903)
Other income
Interest income 44,435 6,488 10,806
- ------------------------------------------------------------------------------------------------------------------------------------
(787,261) (197,829) (148,097)
Write down of inventory (note 8) 55,734 -- --
Write down of product rights and
patent costs (note 3) 374,128 -- --
- ------------------------------------------------------------------------------------------------------------------------------------
Net loss $(1,217,123) $ (197,829) $ (148,907)
====================================================================================================================================
Loss per share $ (0.03) $ (0.03)
====================================================================================================================================
</TABLE>
See accompanying notes to financial statements
<PAGE>
L.O.M. MEDICAL INTERNATIONAL INC.
(A Development Stage Enterprise)
Consolidated Statement of Cash Flows
$ United States
For the six months ended November 30, 1999 and 1998
<TABLE>
<CAPTION>
===================================================================================================================
From inception
(March 17, 1997)
to November 30, 1999 1999 1998
- -------------------------------------------------------------------------------------------------------------------
<S> <C> <C> <C>
Operating activities
Net loss $(1,217,123) $ (197,829) $ (148,097)
Items not involving cash
Amortization 29,778 8,247 8,831
Write down of inventory 55,734 -- --
Write down of product rights 374,128 -- --
Changes in non-cash working capital
Accounts receivable 58,032 2,474 (4,828)
Prepaid expenses (3,352) 1 (543)
Accounts payable and accrued liabilities (6,208) (16,388) (7,534)
Inventory purchases (55,834) -- --
- -------------------------------------------------------------------------------------------------------------------
(764,845) (203,495) (152,171)
Financing
Issuance of capital stock 820,580 186,321 80,377
Issuance of redeemable preferred shares
of subsidiary 309,677 -- --
- -------------------------------------------------------------------------------------------------------------------
1,130,257 186,321 80,377
Investing
Acquisition of capital assets (53,787) -- (38,391)
Acquisition of product rights and patents (381,292) 44 2,891
Acquisition of shares 374,952 --
- -------------------------------------------------------------------------------------------------------------------
(60,127) 44 (35,500)
Other comprehensive income 24,231 --
- -------------------------------------------------------------------------------------------------------------------
Increase (decrease) in cash 329,516 (17,130) (107,294)
Cash, beginning of period -- 346,646 548,197
- -------------------------------------------------------------------------------------------------------------------
Cash, end of year $ 329,516 $ 329,516 $ 440,903
===================================================================================================================
</TABLE>
See accompanying notes to financial statements
<PAGE>
L.O.M. MEDICAL INTERNATIONAL INC.
(A Development Stage Enterprise)
Consolidated Statement of Stockholders' Equity and Comprehensive Income
$ United States
For the six months ended November 30, 1999 and 1998
<TABLE>
<CAPTION>
- ------------------------------------------------------------------------------------------------------------------------------------
Deficit
Accumulated Accumulated
Capital Stock Additional During the Other Total
Number Paid in Development Comprehensive Stockholders'
of Shares Amount Capital Stage Income Equity
- ------------------------------------------------------------------------------------------------------------------------------------
<S> <C> <C> <C> <C> <C> <C>
Common shares issued
net of share issue costs 5,538,849 $ 5,538 $ 1,233,721 $(1,152,030) $ 23,326 $ 110,555
Common shares issued
net of shares issue costs 50,432 75 166,096 -- -- 166,171
Share subscriptions received
for 6,200 shares at $3.25
per share -- 6 20,144 -- 20,150
Foreign currency translation -- -- -- -- -- --
Net loss -- -- -- (197,829) -- (197,829)
- ------------------------------------------------------------------------------------------------------------------------------------
Balance, November 30, 1999 5,589,281 $ 5,619 $ 1,419,961 $(1,349,859) $ 23,326 $ 99,047
====================================================================================================================================
</TABLE>
<PAGE>
L.O.M. MEDICAL INTERNATIONAL INC.
(A Development Stage Enterprise)
Notes to Consolidated Financial Statements
$ United States
For the six months ended November 30, 1999 and 1998
- --------------------------------------------------------------------------------
L.O.M. Medical International Inc. was incorporated on March 17, 1997 under the
General Corporation Laws of Delaware. It conducts research and development on
new products in the medical field and has filed a patent application on a
retractable syringe. Operations effectively commenced on June 1, 1997.
1. Significant accounting policies:
a) Going concern
These financial statements have been prepared on the going concern basis,
which assumes the realization of assets and liquidation of liabilities in
the normal course of business. As shown in the consolidated financial
statements, to date, the Company has accumulated a deficit since inception
of $1,217,123. This factor, among others raises substantial doubt about the
Company's ability to continue as a going concern. The Company's ability to
continue as a going concern is dependent on its ability to generate future
profitable operations and receive continued financial support from its
stockholders and other investors.
b) Translation of financial statements
The Company's subsidiary, L.O.M. Laboratories Inc. operates in Canada and
its operations are conducted in Canadian currency.
The method of translation applied is as follows:
i) Assets and liabilities are translated at the rate of exchange in
effect at the balance sheet date, being US $1.00 per Cdn $1.45
ii) Revenues and expenses are translated at the exchange rate in
effect at the transaction date. iii) The net adjustment arising
from the translation is included in accumulated other
comprehensive income.
c) Basis of presentation and consolidation
The consolidated financial statements include the accounts of the
Company and its 96% owned subsidiary, L.O.M. Laboratories Inc.
d) Product rights and patent costs
Product rights and patent costs relate to amounts paid to acquire the
rights to produce and distribute products as well as the costs
associated with patent applications. These costs are being amortized
on a straight-line basis over five years. Management periodically
reviews the carrying values of the product rights and patent costs and
based upon several factors, including the current assessment of the
viability of the product, determines whether the carrying value
exceeds the net realizable value for such costs. If it is determined
that the carrying value cannot be supported, the related costs are
changed against operations in the year of determination of the
impairment in value.
<PAGE>
L.O.M. MEDICAL INTERNATIONAL INC.
(A Development Stage Enterprise)
Notes to Consolidated Financial Statements, page 3
$ United States
For the six months ended November 30, 1999 and 1998
- --------------------------------------------------------------------------------
1. Significant accounting policies (continued):
e) Capital assets
Capital assets are recorded at cost. Amortization is provided using
the following methods and annual rates which are intended to amortize
the cost of the assets over their estimated useful life:
================================================================================
Asset Method Rate
- --------------------------------------------------------------------------------
Leasehold improvements Straight-line 20%
Computer software Straight-line 100%
Equipment Declining balance 30%
Furniture and fixtures Declining balance 20%
- --------------------------------------------------------------------------------
f) Management estimates
The preparation of financial statements in conformity with generally
accepted accounting principles in the United States of America
requires management to make estimates and assumptions that affect the
reported amounts of assets and liabilities and disclosures of
contingent assets and liabilities at the date of the financial
statements and the reported amounts of revenues and expenses during
the reporting period. Actual results could differ from those
estimates.
g) Financial instruments
The fair values of the Company's cash, accounts receivable and
accounts payable and accrued liabilities approximate their carrying
values due to the relatively short periods to maturity of the
instruments. It is not possible to arrive at a fair value for
redeemable preferred shares as a maturity date is not determinable.
The maximum credit risk exposure for all financial assets is the
carrying amount of those assets.
h) Loss per share
Loss per share has been calculated using the weighted average number of
common shares outstanding during the period.
i) Accounting standards change
In June 1998, the Financial Accounting Standards Board issued
SFAS no. 133, "Accounting for Derivative Instruments and Hedging
Activities." Adoption of this statement is not expected to have a
significant impact on the Company's results of operations or
financial position.
<PAGE>
L.O.M. MEDICAL INTERNATIONAL INC.
(A Development Stage Enterprise)
Notes to Consolidated Financial Statements, page 4
$ United States
For the six months ended November 30, 1999 and 1998
- --------------------------------------------------------------------------------
2. Business combination:
Effective June 1, 1997, the Company acquired 96% of the outstanding Class A
common voting shares of L.O.M. Laboratories Inc. Prior to and immediately
after the acquisition, L.O.M. Laboratories Inc. was controlled by a related
party, the president and controlling shareholder of the Company.
Accordingly, this transaction has been measured at the carrying amount of
the assets and liabilities of L.O.M. Laboratories Inc. with the difference
between the carrying amount and the exchange amount reflected as a charge
to equity. Details of the acquisition are as follows:
- --------------------------------------------------------------------------------
Net assets (liabilities) acquired at carrying amounts
Cash $ 375,000
Non-cash current assets 82,000
Product rights and patent costs 22,000
Capital assets 14,000
Current liabilities (26,224)
Share subscriptions (605,000)
Minority interest 5,536
- --------------------------------------------------------------------------------
(132,688)
Excess of consideration given over carrying amount
of net assets acquired 132,736
- --------------------------------------------------------------------------------
Consideration given:
Cash $ 48
================================================================================
3. Product rights and patent costs:
================================================================================
1999
- --------------------------------------------------------------------------------
Product rights $ --
Patent costs 14,588
- --------------------------------------------------------------------------------
$ 14,588
================================================================================
Product rights represent certain rights to manufacture and market a contact
lens inserter and storage system ("Lens-o-matic") developed by the
president of the Company.
At the time of the acquisition of the product rights from the president of
the Company, the value attributed to the product rights, $380,885, was
agreed to by the Company's Board of Directors. During the year ended May
31, 1999, the investment was written down to a nominal amount, due to its
speculative nature.
Patent costs relate to the costs incurred for patent application for a
retractable syringe developed by the Company.
<PAGE>
L.O.M. MEDICAL INTERNATIONAL INC.
(A Development Stage Enterprise)
Notes to Consolidated Financial Statements, page 5
$ United States
For the six months ended November 30, 1999 and 1998
======================================================================
4. Capital assets:
======================================================================
1999
- ----------------------------------------------------------------------
Accumulated Net book
Cost amortization value
- ----------------------------------------------------------------------
Leasehold improvements 27,919 8,376 19,543
Computer software 520 455 65
Equipment 20,948 11,746 9,202
Furniture and fixtures 20,746 5,826 14,920
- ----------------------------------------------------------------------
$70,133 $26,403 $43,730
======================================================================
5. Redeemable preferred shares:
The Company's subsidiary has redeemable preferred shares outstanding as
follows:
<TABLE>
<CAPTION>
======================================================================================================
1999 1998
- ------------------------------------------------------------------------------------------------------
<S> <C> <C>
Issued:
4,000 Class C preferred shares with a par
value of $100 Cdn redeemable at $110.16 Cdn per share
at the option of the holder. Each share is entitled to a fixed
non-cumulative dividend at the rate of 9% per annum
payable at such times as determined by the Directors. 301,727 309,677
======================================================================================================
</TABLE>
<PAGE>
L.O.M. MEDICAL INTERNATIONAL INC.
(A Development Stage Enterprise)
Notes to Consolidated Financial Statements, page 6
$ United States
For the six months ended November 30, 1999 and 1998
================================================================================
6. Capital stock:
a) Authorized:
50,000,000 Common shares with a par value of $.001 each
5,000,000 Preferred shares with a par value of $.001 each
b) Share subscriptions:
Subsequent to November 30, 1999, the Company issued 6,200 common
shares at $3.25 per share for net proceeds of $20,144, which were
received prior to November 30, 1999.
c) Stock option plan:
1,000,000 common shares of the Company are reserved for issuance upon
exercise of stock options. As at May 31, 1999, no stock options have
been granted.
7. Related party transactions:
During the year the Company entered into the following transactions
with related parties:
================================================================================
1999
- --------------------------------------------------------------------------------
Legal and accounting fees paid to a director $ 6,718
Management fees paid to president 60,000
Office and administration fees paid to president's spouse 18,000
Office and administration fees paid to an individual
related to the president 8,040
Rent paid to a company controlled by the president 17,717
- --------------------------------------------------------------------------------
These transactions are in the normal course of operations and are measured
at the exchange amount of consideration established and agreed to by the
related parties.
<PAGE>
L.O.M. MEDICAL INTERNATIONAL INC.
(A Development Stage Enterprise)
Notes to Consolidated Financial Statements, page 7
$ United States
For the six months ended November 30, 1999 and 1998
- --------------------------------------------------------------------------------
8. Commitments:
The Company is obligated to make future lease payments for its offices as
follows:
2000 $ 36,913
2001 $ 19,453
2002 $ 19,453
2003 $ 19,453
2004 $ 19,453
9. Uncertainty due to the Year 2000 Issue:
The Year 2000 Issue arises because many computerized systems use two digits
rather than four to identify a year. Date-sensitive systems may recognize
the year 2000 as 1900 or some other date, resulting in errors when
information using Year 2000 dates is processed. In addition, similar
problems may arise in some systems which use certain dates in 1999 to
represent something other than a date. The effects of the Year 2000 Issue
may be experienced before, on, or after January 1, 2000, and, if not
addressed, the impact on operations and financial reporting may range from
minor errors to significant systems failure which could affect an entity's
ability to conduct normal business operations. It is not possible to be
certain that all aspects of the Year 2000 Issue affecting the entity,
including those related to the efforts of customers, suppliers, or other
third parties, will be fully resolved.
Item 2. Management's Discussion and Analysis or Plan of Operation
Development of the Registrant. L.O.M. Medical International Inc., a Delaware
corporation ("Company"), was incorporated in the State of Delaware on March 17,
1997. The executive offices of Registrant are located at #580-885 Dunsmuir
Street, Vancouver, British Columbia, Canada V6C 1N8. Registrant's telephone
number is 604.602.9400.
As a point of clarification, as used in this Registration Statement, the word
"Dollars" and the symbol "$" means and refers to the currency of the United
States of America, unless otherwise stated. As used in this Registration
Statement, the term "CDN$" means and refers to the currency of Canada, in
Canadian dollars.
Registrant was originally incorporated for the purpose of researching and
developing health care products. The goal of Registrant is to become an
innovator and provider of a retractable syringe ("Syringe") and related products
and technologies to the health care market. Registrant also hopes to
successfully market and distribute its line of eye care products. Registrant has
successfully patented and licensed products in twenty-four other countries
including the United States and Canada. Registrant envisions that it will be
able to develop new and improved products and provide the health care industry
with better, safer products throughout the world.
The Syringe. Registrant anticipates that the Syringe will change standard
disposal methods for used syringes. In this regard, Registrant has developed a
product designed to function as a standard hypodermic syringe with one
difference: it is safer and less perilous to the caregiver or health care
worker. Registrant believes that the Syringe's unique design will allow health
care providers to avoid direct contact with used needles. The Syringe is covered
by United States Patent No. 5,868,713 dated February 9, 1999, and international
patents have been filed in 24 different countries.
Once the needle is injected, the user simply has to press the plunger top gently
with his or her thumb to automatically retract the needle into its own sealed
chamber. The needle is now hidden where it remains locked in place and cannot be
used again. The Syringe does not require a health care worker to use both hands
to retract the needle after it has been used and withdrawn from the patient. The
Syringe will be produced in standard industry sizes from 1CC to 20 CC,
inclusive. Registrant anticipates that the products and technologies developed
by Registrant will be offered to distributors on a worldwide basis, with an
initial emphasis in Canada and the United States.
Registrant anticipates that it will be testing the Syringe in conjunction with
teaching universities in Canada, Britain, and other constituents of the United
Kingdom. Registrant has also developed ancillary components to be used in
medical emergency situations and which can also be used by hospital medical
staff and paramedics.
The Lens-O-Matic. Registrant has invented and developed an insertion and storage
device for contact lenses (the "Lens-O-Matic") which is an ideal medical method
of handling and inserting contact lenses. Registrant has developed the following
components and solutions that will be used together with the Lens-O-Matic
insertion and storage system: (1) a medical inserter that will remove contact
lenses in a medical emergency situation for use by hospital medical staff and
paramedics; (2) disposable and replacement inserter ends; (3) additional storage
cups and caps; and (4) all soaking and disinfecting solutions that are to be
used with the Lens-O-Matic inserter.
The Lens-O-Matic is designed so that the practitioner will no longer have direct
hand or finger contact with the contact lens when fitting the patient.
Registrant believes that the design of the Lens-O-Matic will reduce the risk of
contamination and infection to the patient. Registrant has developed a liquid
cleaner for the Lens-O-Matic that quickly cleans contact lenses. Registrant has
obtained Food and Drug Administration Approval ("FDA") for the Lens-O-Matic
product. Registrant has also completed market testing and believes that the
Lens-O-Matic was well received at the A.O.A. convention in Montreal, Canada,
where approximately 30,000 units were distributed to opticians, optometrists and
pharmacies. Registrant has also completed the formulation of its contact lens
solutions and copyrights covering
2
<PAGE>
these products have been registered. Registrant has also completed the design
and labeling of the Lens-O-Matic package. Registrant believes that its eye-care
products are ready for marketing and distribution.
The target markets for the distribution for the Lens-O-Matic product include,
but are not necessarily limited to, (i) hospitals and clinics, including
Shippert Medical of Englewood, Colorado ("Shippert"), Cross Mark Sales &
Marketing of Plano, Texas; and (ii) optometrists and opticians including, Health
Care Insights of Edison, New Jersey.
The Syringe. Registrant anticipates that it will obtain the necessary plastic
for the injection molds used to manufacture the Syringe from various domestic
and international suppliers. Initially, Tessey Plastics of Elbridge, New York
will be manufacturing the Syringe on a contract basis. The engineering for the
molds and dyes are near completion. Registrant also contemplates that it will be
able to readily obtain the necessary packaging for the Syringe. Registrant does
not believe that its sales will be affected by seasonal factors. Registrant
believes that prototypes of the Syringe will be ready for testing in March,
2000. Registrant believes that it will complete testing in Canada and gain the
necessary regulatory approvals in or around June, 2000. Registrant believes it
will complete the necessary United States testing as well as secure the required
United States regulatory approval in or around September, 2000.
As previously discussed, Registrant hopes to eventually establish a production
facility in Spokane, Washington. It is anticipated that the facility will
initially produce approximately 2,500,000 units of the Syringe per month with
the capacity to meet increased market demands. Registrant believes that it will
deliver its products to the North American markets by courier. All supply and
distribution agreements will be negotiated by Health Care Insights.
Once testing of the Syringe is completed, and assuming FDA approval is received,
Registrant hopes to manufacture, or cause to be manufactured, a specified number
of units of the Syringe, which will be provided, at no charge, to a target group
of physicians for testing. Registrant plans to provide units to various
individuals who are to form part of the testing group. These individuals will be
asked to try the Syringe and report their findings. Registrant will then utilize
professionals such as doctors and related health care professionals who approve,
recommend and endorse Registrant's products, including the Syringe. Thereafter,
Registrant anticipates that the Syringe will be supplied to large national
distributors within specific regions all over the world. Registrant anticipates
that the distributors will thereafter market the Syringe to pharmacy and medical
supply companies. Registrant's overall operating plan is to act as a
manufacturer, selling directly and only to distributors and retail chains.
Registrant hopes that the product will gain acceptance in the medical community
and that Registrant's skill in positioning and merchandising the products and
technology of Registrant will enable it to acquire a commercially reasonable
portion of the market.
Lens-O-Matic. Registrant anticipates that its eye care products will be sold
both by retail stores and as a kit distributed by the medical profession.
Registrant expects that its eye care products will be sold through pharmacies,
wholesale drug distributors and chain stores and that such products will be sold
to Optometrists and Ophthalmologists directly by Registrant's sales
representatives. Registrant has recently secured FDA approval for the
manufacturing and distribution of a first product run of its eye-care products.
We have developed our own dyes and injection molds for our Lens-O-Matic and
related products. We have paid for all of the dyes and molds and currently own
them. The first product run of our eye care products includes the utilization of
our production dyes at full capacity, the production of a marketable product
which exceeds FDA standards for medical devices. We manufacture the necessary
components for the Lens-O-Matic and related products in Saskatchewan, Canada.
Registrant is currently negotiating with Shippert Medical Technologies of
Englewood, Colorado ("Shippert") pursuant to which Registrant anticipates that
Shippert will distribute Registrant's product line in the United States.
Registrant anticipates that the marketing of its eye-care products will begin in
early 2000.
Registrant plans to focus its initial marketing efforts in Canada and the United
States. Registrant hopes to eventually expand its product marketing and sales
into Europe, South America, Central America, Mexico and Asia. Registrant plans
to market its products by advertising in catalogs and medical journals, by
distributing brochures (both written and video), by direct mail and by posters.
Follow-up calls will be made to promising prospects. This approach will be
Registrant's primary marketing method. It is expected that Registrant's
personnel will attend various trade shows and medical conventions in order to
introduce the Syringe with the hope of gaining endorsements and approvals. There
can be no assurance that Registrant would be able to establish successfully
other methods of marketing and sales of its
<PAGE>
products should it become necessary or desirable in the future. A significant
portion of Registrant's sales may be made through independent distributors over
which Registrant has no control and who also will represent products of other
companies. Registrant recognizes that in order to increase market awareness and
the marketing potential of its products, it must hire adequate personnel and
institute effective advertising in the most cost effective way.
Registrant is not currently producing commercial quantities of its products nor
is it currently supplying any services to any third parties. No assurance can be
given that Registrant, on a timely basis, will be able to make the transition
from manufacturing testing quantities of the Syringe to commercial production
quantities successfully or be able to arrange for contract manufacturing.
Registrant has produced testing quantities amounting to 33,000 units of its eye
care products. Registrant's current production capacity does allow for the
production of commercial quantities of its eye care products, with its present
dyes allowing for the production of 75,000 units per month. Registrant believes
that this can be increased to 150,000 units by running additional shifts.
Registrant has a second set of dyes designed that will have a 300,000 unit
capacity which would allow the production for a total of 450,000 units of its
eye care products per month. Registrant does anticipate that it will be able to
manufacture its products for initial commercialization.
Registrant anticipates that it will contract out the first two years of
production of the Syringe. At the end of the second year of production,
Registrant anticipates it will engage in significant discussions regarding the
potential for the construction of its own production facility. Registrant
recognizes that the construction of its own production facility will be
contingent upon its having reached its sales and profit projections. Registrant
anticipates that it will present this issue for vote by its Board of Directors
and shareholders. In this regard, Registrant anticipates that it will locate its
production facilities in North America, specifically, the state of Washington,
due to its strategic location for penetration into the United States and
Canadian markets.
As previously discussed, Registrant's eye care products are currently produced
in Canada. Registrant owns all of the necessary injection molds. Registrant
contracts out for the production of components needed for the assembly and
packaging of its eye care products. The actual assembly and packaging are done
by Registrant's own work force. All other products of Registrant, those either
currently in production or the subject of future production will be produced on
a contract basis through plants that are FDA approved for production of medical
products.
Registrant is currently negotiating with the Irish Development Board in Ireland
("Development Board"). Representatives from the Development Board have met with
Registrant's Board of Directors on 3 different occasions and have offered to
assist Registrant in establishing a production facility in Ireland. Registrant
has already sent representatives to Ireland to discuss the production of the
Syringe as well as strategic alliances for market distribution of all
Registrant's products. Registrant's plans to construct a production facility are
merely preliminary. As such, Registrant has not reached an estimation of the
capital resources necessary to fund such a project nor has Registrant determined
how long such a project would take to complete. Registrant anticipates that at
the end of the projected two-year period, Registrant will have a sufficient
revenue stream to finance, at least partially, the construction of the proposed
production facilities. However, there can be no assurance that Registrant will
have the necessary funds at the end of the two-year period to construct its
proposed production facilities. Should Registrant not have the necessary funds,
Registrant anticipates it will continue to cause its products to be produced on
a contract basis.
Currently, Registrant does have the necessary production facilities to produce
its line of eye care products on a commercial basis. Registrant has FDA approval
to market its line of eye care products in the United States. Also, as
previously discussed, Registrant has the necessary Canadian approval to market
its eye-care products in Canada. Shippert Medical will be marketing Registrant's
eye care products in the United States as well as in Canada. Registrant has
entered into a marketing and distribution contract with Shippert Medical. The
contract has an initial two-year term with a two-year renewal option.
Business of Registrant's Subsidiary. On or about June 1, 1997, Registrant agreed
to purchase 4,800 of the 5,000 total issued and outstanding shares of L.O.M.
Laboratories Inc.'s ("L.O.M. Laboratories") Class "A" common shares. Registrant
agreed to pay US$1.00 per share. This represents a 96% interest in L.O.M.
Laboratories. L.O.M. Laboratories owned the rights to the Lens-O-Matic system
until January 1, 1998, when Registrant purchased those
4
<PAGE>
rights for US$380,885. The primary business purpose of the subsidiary is to
develop and market new products through Registrant.
Liquidity. The Registrant had cash resources of US$440,903 at November 30, 1998.
At November 30, 1999, the Registrant had cash resources of US$329,516.00. At
November 30, 1999, the Registrant had total current assets of US$356,936.00 and
total current liabilities of US$20,016.00. At November 30, 1999, total current
assets exceeded total current liabilities by US$336,920.00. The cash and
equivalents constitute the Registrant's present internal sources of liquidity.
Because neither the Registrant nor its subsidiary are generating any significant
revenues, the Registrant's only external source of liquidity is the sale of its
capital stock.
Results of Operations. The Registrant has not yet realized any significant
revenue from operations. Loss from operations from March 17, 1997 (inception) to
November 30, 1999, was US$1,217,123.00. The net loss for the 3-month period
ended November 30, 1998 was US$148,097.00. The net loss for the 3-month period
ended November 30, 1999, was US$197,829.00. Such losses were primarily the
result of selling, general and administrative expenses, management fees, rent
and consulting fees.
The Registrant may require additional cash to implement its business strategies,
including cash for (i) payment of increased operating expenses and (ii) further
implementation of those business strategies. No assurance can be given, however,
that the Registrant will have access to the capital markets in the future, or
that financing will be available on acceptable terms to satisfy the cash
requirements of the Registrant to implement its business strategies. The
inability of the Registrant to access the capital markets or obtain acceptable
financing could have a material adverse effect on the results of operations and
financial conditions of the Registrant.
The Registrant's forecast of the period of time through which its financial
resources will be adequate to support its operations is a forward-looking
statement that involves risks and uncertainties, and actual results could vary
as a result of a number of factors.
The Registrant anticipates that it will need to raise additional capital within
the next 12 months in order to develop, promote, produce and distribute its
proposed products. Such additional capital may be raised through additional
public or private financings, as well as borrowings and other resources. To the
extent that additional capital is raised through the sale of equity or
equity-related securities, the issuance of such securities could result in
dilution of the Registrant's stockholders. There can be no assurance that
additional funding will be available on favorable terms, if at all. If adequate
funds are not available within the next 12 months, the Registrant may be
required to curtail its operations significantly or to obtain funds through
entering into arrangements with collaborative partners or others that may
require the Registrant to relinquish rights to certain of its products that the
Registrant would not otherwise relinquish.
Registrant, being a developmental stage enterprise, is currently putting
technology in place which will, if successful, mitigate the net loss experienced
by Registrant. Registrant is reviewing its options to raise substantial equity
capital. Management has proceeded as planned in the ongoing development of the
Syringe and the Lens-O-Matic. In order to meet its requisite budget, management
has held and continues to conduct negotiations with investors. Registrant has
also conducted extensive negotiations with various medical companies in an
attempt to establish beneficial strategic alliances. Registrant hopes that these
negotiations will result in significant investment income for Registrant. To
achieve and maintain the competitiveness of its products and to conduct costly
and time-consuming research and development, Registrant may be required to raise
substantial funds in addition to the funds already raised through the issuance
of Registrant's shares. Registrant's forecast for the period of time through
which its financial resources will be adequate to support its operations is a
forward-looking statement that involves risks and uncertainties, and actual
results could fail as a result of a number of factors. Registrant anticipates
that it will need to raise additional capital in order to develop, promote,
produce and distribute its products. Such additional capital may be raised
through additional public or private financings, as well as borrowings and other
resources.
There can be no assurance that additional funding will be available under
favorable terms, if at all. If adequate funds are not available, Registrant may
be required to curtail operations significantly or to obtain funds through
entering into arrangements with collaborative partners or others that may
require Registrant to relinquish rights to certain products
5
<PAGE>
that Registrant would not otherwise relinquish. However, Registrant believes
that it is poised to maintain its long-term liquidity. Management of Registrant
believes that its plans described above will enable it to meet its obligations
for a period of at least twelve (12) months from November 30, 1999. Registrant
believes that within a short period of time, it can begin manufacturing and
marketing commercial quantities of its eye care products. Coupled with the
further issuance of common stock of Registrant, Registrant believes it can
significantly improve its long-term liquidity.
The Registrant does not anticipate any material expenditures within the next 12
months. The Registrant does not anticipate any significant research and
development within the next 12 months, nor does the Registrant anticipate that
it will lease or purchase any significant equipment within the next 12 months.
The Registrant does not anticipate a significant change in the number of its
employees within the next 12 months.
Item 3. Defaults Upon Senior Securities
None
Item 4. Submission of Matters to Vote of Security Holders
None
Item 5. Other Information
None
Item 6. Exhibits and Reports on Form 8-K
None
6
<PAGE>
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the
Registrant has duly caused this report to be signed on its behalf by the
undersigned thereunto duly authorized.
Dated: February 17, 2000 L.O.M. Medical International, Inc.
By:/s/ John Klippenstein
-----------------------
John Klippenstein
Its: President
7
